Menton

Domperidone

Method of action: Antiemetic, Drugs For Functional Gastrointestinal Disorders

Treatment option: Pain, Heartburn, Flatulence, Belching, Oral Cavity, Burping, Reflux, Morning Sickness, Esophagitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Menton

Quick Facts

Property	Description
Active ingredient	Domperidone
Form	Tablets, Oral Suspension, Suppositories
Pharmacological class	Dopamine Antagonist, Prokinetic agent
General purpose	Manages gastrointestinal motility and nausea
Origin	Synthetic organic molecule

What Type of Medicine is Menton?

Menton is a pharmaceutical product containing the compound Domperidone. It is categorized as both a Dopamine Antagonist and a Prokinetic agent. This medication is a single-active ingredient product of synthetic origin, defined by the chemical formula C22H24ClN5O2. This dual classification reflects its function: it counteracts the effects of dopamine in the gastrointestinal tract to help restore normal movement. Domperidone is characterized by its peripherally selective action, meaning it primarily interacts with dopamine receptors in the peripheral system with minimal penetration across the blood-brain barrier.

Composition and Available Pharmaceutical Preparations

The sole therapeutic agent in Menton is Domperidone. It is produced in various dosage forms to accommodate different patient requirements and routes of administration. Common pharmaceutical preparations include standard tablets, orally disintegrating tablets (ODTs), and an oral suspension, which is often utilized for patients with swallowing difficulties or when precise dosing is required for adolescents. It may also be formulated as suppositories for rectal administration in cases where the oral route is not feasible. These various forms—utilizing either a solid excipient matrix or an aqueous vehicle—are designed to ensure the delivery of the active substance.

General Purpose and Peripheral Action

The primary purpose of this medication is to manage discomfort and functional symptoms associated with slow upper digestive motility, specifically addressing sensations of sickness. Domperidone works by helping to suppress the neural signals that trigger nausea and vomiting while simultaneously enhancing gastric motility. This action is intended to facilitate gastric emptying. It is used to provide relief in scenarios involving chronic feelings of fullness or indigestion, serving as a functional gastrointestinal agent.

What side effects are possible with Menton?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints of Menton (Domperidone), strictly based on government regulatory sources.

Serious Adverse Reactions and Cardiac Risk

Safety warnings highlight the risk of serious heart rhythm problems, including ventricular arrhythmias, Torsades de Pointes, and sudden cardiac death. Regulatory bodies have noted that this risk may be heightened at the start of treatment and is associated with higher daily doses.

System Organ Class (SOC)	Frequency Classification	Examples of Adverse Reactions
Cardiovascular Disorders	Not known	Ventricular arrhythmia, Sudden cardiac death
Gastrointestinal Disorders	Common / Uncommon	Dry mouth, Diarrhoea
Nervous System Disorders	Uncommon / Rare	Headache, Somnolence, Extrapyramidal disorders
Reproductive System Disorders	Uncommon / Not known	Galactorrhoea, Gynaecomastia
Immune System Disorders	Uncommon / Not known	Hypersensitivity reaction, Anaphylactic reactions

Safety Restrictions and Contraindications

Official regulatory documents define specific conditions under which Menton must not be used (contraindicated) due to heightened risk:

Cardiac Conditions: In patients with existing heart conditions such as congestive heart failure, QTc prolongation, or significant electrolyte disturbances (e.g., hypokalaemia).
Hepatic Impairment: In individuals with moderate or severe hepatic impairment (liver failure).
Concomitant Medicines: When taken alongside certain QT-prolonging medicines or potent CYP3A4 inhibitors.
Prolactinoma: In patients with a known prolactin-releasing pituitary tumor.

Safety notes also indicate an increased risk of cardiac events in older adults (typically over 60 years of age). These regulatory statements dictate the strict limits of the medicine's use.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory documents describe a Menton overdose as potentially affecting both the cardiovascular and central nervous systems. Documented neurological and motor signs include disorientation, dizziness, difficulty in speaking ( dysarthria), and loss of balance or muscle control ( Extrapyramidal Symptoms). The critical risk is cardiovascular toxicity, which may present with irregular heartbeat or fainting. Severe outcomes cited in official labeling include QTc prolongation, serious ventricular arrhythmias, and sudden cardiac death.

Mandatory Emergency Action and Management

In the event of suspected overdose, seek immediate medical attention or contact emergency services immediately. Urgent medical evaluation is required if any cardiac symptoms are observed, such as an irregular heartbeat or fainting. Treatment is symptomatic and supportive, and continuous ECG monitoring must be initiated due to the mandated observation of QTc prolongation risk. Regulatory documents state that no specific antidote is known. Procedural measures to reduce absorption, such as gastric lavage or activated charcoal, may be considered following recent oral ingestion.

Population and Dose-Related Risk

Regulatory information notes an increased risk of serious cardiac events associated with daily doses greater than 30 mg. This risk is officially documented as higher in patients older than 60 years and in those with pre-existing conditions like electrolyte disturbances or underlying cardiac diseases.

Therapeutic Uses of Menton

What Menton Treats: Main Uses and Benefits

Menton is commonly used to provide symptomatic relief from the distressing sensations of nausea and the physical act of vomiting. This medication is utilized for the relief of these symptoms, helping to address symptom clusters that may become intense or disruptive, and offering supportive therapeutic benefit to ease the overall symptom load.

The medication plays a role in managing groups of symptoms associated with impaired upper digestive movement, such as Gastroparesis and Functional Dyspepsia. Its use is relevant in managing symptoms related to chronic fullness, bloating, early satiety, and upper abdominal discomfort. It may also be applied in specific clinical scenarios, such as managing gastrointestinal distress associated with medications for Parkinson's disease or in palliative care contexts.

“May assist in supporting comfort and functional stability by easing the persistent symptom burden of sickness and upper abdominal distress.”

This approach is relevant in clinical settings marked by heightened patient distress, as it may help patients cope more steadily with symptom fluctuations, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Sickness and Fullness
Primary Symptom Domains	Nausea, Vomiting, Early Satiety, Abdominal Bloating
Main Therapeutic Role	Supportive management of sickness and slow upper digestive movement
Clinical Relevance	Functional Dyspepsia, Diabetic Gastroparesis, Drug-induced GI distress
Patient Benefit	Contributes to easing the overall symptom load and helps maintain functional stability

Regulatory References

Medicines and Healthcare products Regulatory Agency (MHRA) in the UK

Eligibility and Restrictions for Use

Eligibility for Menton (Domperidone)

Official regulatory guidelines define specific age, weight, and health requirements for the use of Menton. The medicine is authorized for use in adults and adolescents aged 12 years and older who weigh at least 35 kilograms.

Contraindicated Populations

Use is strictly prohibited (contraindicated) for patients with the following conditions, as these groups are considered non-eligible based on regulatory findings:

Moderate or severe hepatic impairment (liver disease).
Underlying cardiac diseases such as congestive heart failure, known prolongation of the QTc interval, or significant electrolyte disturbances.
Gastrointestinal conditions where stimulating motility would be harmful, such as haemorrhage, mechanical obstruction, or perforation.
Patients concomitantly taking potent CYP3A4 inhibitors or certain QT-prolonging medicines.

Restricted and Conditional Use

Children: Use is generally not recommended in children under 12 years or adolescents weighing less than 35 kg due to lack of established efficacy data.
Older Adults: Use requires caution due to a documented elevated risk of serious ventricular arrhythmias.
Renal Impairment: Patients with severe kidney impairment require a mandatory reduction in dosing frequency.
Pregnancy and Lactation: Use during pregnancy is generally considered only when the therapeutic benefit is justified. Use during lactation is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Menton (Domperidone) is structured around two categories of interactions that mandate strict prohibitions on co-administration.

Formally Contraindicated Combinations

Menton is primarily metabolized by the CYP3A4 enzyme. Regulatory authorities mandate that co-administration is strictly prohibited with medicines and products that are potent CYP3A4 inhibitors. These include certain macrolide antibiotics (e.g., clarithromycin), systemic azole antifungals, and specific HIV protease inhibitors, as they significantly increase Menton's plasma concentration and risk.

Co-administration is also prohibited with any medicine classified as a strong QT-prolonging drug due to the resulting additive risk of serious ventricular arrhythmias.

Interaction Type	Regulatory Status	Example Categories
Metabolic Inhibition	Contraindicated	Potent CYP3A4 Inhibitors
Pharmacodynamic	Contraindicated	Strong QT-prolonging drugs

Mechanism of Action

How Menton Works

Menton operates through a highly selective peripheral dopamine receptor blockade, primarily targeting the Dopamine D2 (D2) receptors. The molecule's mechanism is defined by its minimal functional penetration of the blood-brain barrier (BBB), concentrating its effect in the peripheral nervous system and the Chemoreceptor Trigger Zone (CTZ). Antagonism at D2 receptors in the CTZ modulates the signaling pathways of the emetic reflex, suppressing the neurological cascade initiated by receptor activation.

The same D2 receptor blockade occurs on inhibitory nerve endings within the upper digestive tract's enteric nervous system. This action removes inhibitory dopamine tone, functionally promoting the local release of acetylcholine, the neurotransmitter that governs muscle contraction. This modification of signaling dynamics enhances the coordination and force of peristalsis, leading to an acceleration of gastric emptying and an increase in Lower Esophageal Sphincter (LES) pressure. This peripheral nature also establishes a constraint on the mechanism's influence, limiting its effect in physiological scenarios where the emetic reflex is predominantly driven by centralized, non-dopaminergic pathways.

Dosage and Administration Information

Menton (Domperidone) is utilized according to specific procedural guidelines regarding its usage patterns. The medicine is available for oral intake in the form of tablets or oral suspension, and for rectal administration as suppositories.

Official Administration Guidelines

Feature	Labeled Instruction
Route of Administration	Oral and Rectal (suppositories only).
Maximum Dosing Limit	Adults and adolescents (12 years of age or older, weighing 35 kg or more) should not exceed 30 mg per day (10 mg up to three times daily). Rectal dosing is limited to 30 mg up to twice daily.
Timing Relative to Food	Oral formulations should be taken before meals, as food intake can delay the drug’s absorption.
Duration of Treatment	Use must be for the shortest duration possible, and treatment should not usually exceed seven consecutive days.

Population-Specific Use

For pediatric patients weighing less than 35 kg, tablets and suppositories are generally unsuitable due to the need for accurate, weight-based dosing. The oral suspension is used, with a recommended dose of 0.25 mg/kg body weight per intake, up to three times daily. In cases of severe renal impairment, the dosing frequency must be reduced (for example, to once or twice daily) due to prolonged drug elimination.

Missed Dose and Preparation

If a dose is missed, the dose should be omitted and the usual schedule resumed; the dose must not be doubled to compensate. When using the oral suspension, a calibrated device is required for measuring the correct amount. Oral tablets must be swallowed whole and should not be crushed.

This structured approach describes the limits for frequency, duration, and dosage established for this medication.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Menton

Evidence for Symptomatic Relief of Nausea and Vomiting

The evidence base for Menton's role in addressing symptoms of sickness and the act of throwing up primarily consists of short-term Randomized Controlled Trials (RCTs) and scientific reviews. These studies have been used in research exploring how symptoms change over time in the acute setting. Research has studied for outcomes related to episodic or acute changes, focusing on patients whose symptoms are disruptive or heightened. The study populations were mainly adults and, in some cases, adolescents (aged 12 and older).

Research highlights changes measured during the study period in the frequency of vomiting and the patient's reported intensity of nausea, typically over durations of up to seven days. Systematic reviews of these findings describe patterns observed in the studies that supported the study of its role in managing these acute symptoms. Studies for this acute condition are primarily short-term.

The majority of controlled trials were designed for short-term evaluation. Furthermore, the evidence quality varies across studies, and there is limited information regarding its role in very young children, where some studies observing responses over defined time intervals did not describe a difference compared to placebo.

Evidence for Managing Functional Dyspepsia Symptoms

Studies explored Menton's potential role in managing functional dyspepsia (FD), a condition characterized by fluctuating or episodic manifestations such as prolonged feelings of fullness, early satiety, and upper abdominal bloating. Research designs typically involved intermediate-term controlled clinical trials, often spanning two to eight weeks. These trials examined outcomes related to physical discomfort and changes in physiological function, such as measured gastric emptying time.

Some studies reported how symptoms evolved in the observed populations, describing patterns observed in the studies where patients reported changes in specific discomfort symptoms compared to those receiving placebo. However, scientific reviews indicate that the findings were mixed across the entire body of research. The evidence contributes to the broader evidence landscape, but certainty remains low due to heterogeneity (variability) in how studies were conducted and the different ways symptoms were measured.

The follow-up durations were limited, focusing on immediate relief rather than sustained management. The research exploring short-term symptom changes does not determine whether an individual will respond similarly, as subgroup findings are uncertain within the diverse population of patients with functional dyspepsia.

Evidence for Use in Gastroparesis (Refractory Symptoms)

For patients with diabetic or idiopathic gastroparesis—a condition marked by functional limitations and often refractory (unresponsive) to standard care—research has evaluated in these complex populations using different study designs. Because of the chronic nature of the condition, much of the data is derived from long-term observational settings and specialized registry data, rather than large-scale, placebo-controlled RCTs.

These observational studies monitored patient-reported outcomes describing perceived discomfort, such as the Gastroparesis Cardinal Symptom Index (GCSI) scores, over extended periods. Data show patterns related to patterns reported for symptom scores in severely affected patients over time. This evidence, which is derived from settings with varying symptom burdens, helps contextualize how patients reported their experience when the medication was observed in patients with severe, chronic illness.

Since the data are largely derived from non-randomized observational studies, comparative evidence is lacking. The results apply only to the populations studied, which are frequently patients with severe symptoms who have already failed other treatments. Long-term effects are not fully established through controlled trials, and the research provides context but not individual predictions for newly diagnosed cases.

Long-Term Outcomes and Extended Follow-up

The majority of formal clinical trials examining initial efficacy for nausea, vomiting, and functional dyspepsia are designed for short-term evaluation, typically lasting a few days up to a couple of months. Therefore, there is limited information for long-term outcomes regarding the sustained changes associated with Menton over many months or years.

In the case of refractory gastroparesis, while patients was observed in long-term registries, these are observational settings. This means that while data show patterns related to changes in symptom management over long durations (sometimes over a year), the methodology does not provide the same certainty as a long-term randomized controlled trial. Long-term effects and the durability of any observed response are areas where research is ongoing and controlled data remain insufficient.

Evidence in Specific Populations

Research has studied for its use in adolescents (12 years and older), primarily for symptomatic relief, with these groups included in the general study populations. Specific attention has also been paid to patients with comorbidities, such as those using certain medications for Parkinson’s disease, where its use was evaluated alongside co-administered medications.

However, data for certain groups remain insufficient. For instance, evidence for patients with specific cardiac health issues or frail older adults is often viewed under stricter regulatory scrutiny. Limited information for long-term outcomes means that the changes associated with using the medication for sustained periods in any specific high-risk subgroup are not fully established.

Research Gaps and Areas of Uncertainty

The body of research, while providing foundational context, indicates several areas of uncertainty. The evidence quality varies across studies, particularly for the functional dyspepsia indication, where findings were mixed. The follow-up durations were limited in many controlled trials, leaving gaps in understanding long-term patterns and potential symptom recurrence.

A primary limitation is that much of the available evidence is older, and comparative evidence against contemporary treatments is not fully characterized in the reviewed literature. Scientific summaries also note that for severe, chronic conditions like gastroparesis, the evidence is often non-randomized, meaning the research does not determine whether an individual will respond similarly and evidence quality varies across studies depending on the design. Research continues to explore these areas to strengthen the overall understanding of Menton's role and what has been explored and what remains uncertain.

Key Studies & References

Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia

Frequently Asked Questions (FAQ)

Common questions about Menton (FAQ)

Q: How long does it typically take for Menton to start having an effect?

Studies of the medicine's absorption indicate that peak levels in the bloodstream are generally reached within 30 to 60 minutes after taking it. This timing is based on taking the medicine on an empty stomach, which is the official condition for use.

Q: Does Menton interact with common over-the-counter pain medications?

Official product information states that caution is necessary when combining Menton with any other medicine or product. This includes non-prescription pain relievers, as certain combinations can increase the risk of side effects. Information regarding the use of Menton alongside non-prescription products should be reviewed with a healthcare provider.

Q: Does Menton treat the root cause of the condition or just the symptoms?

Menton is classified as a prokinetic agent and a dopamine antagonist. Its authorized purpose is to provide relief for symptoms related to nausea, vomiting, and certain types of dyspepsia. Regulatory documents describe its function as managing discomfort and functional movement rather than treating the underlying disease cause.

Q: What types of mental health side effects, if any, are associated with Menton?

The official side effect lists categorize certain events under Nervous System Disorders. These include somnolence (drowsiness) and extrapyramidal disorders, which are involuntary movement issues. A healthcare professional should be contacted if a person experiences new or unusual neurological or psychological symptoms.

Q: Does Menton interact with alcohol consumption?

Official patient safety information strongly recommends against consuming alcohol during treatment with Menton. Alcohol may increase the risk of known side effects, such as dizziness, headache, and drowsiness.

Q: Can Menton be taken safely with vitamins or herbal supplements?

Regulatory labeling indicates that the use of all herbal remedies, vitamins, and supplements should be reviewed by a healthcare provider. There is often insufficient data regarding the safety and potential effects of these combinations, and certain supplements may interfere with the drug's metabolism.

Q: Are there any restrictions on operating machinery or driving while taking Menton?

Regulatory documents advise patients to use caution because side effects like dizziness or drowsiness (somnolence) are known to occur. Patients are advised not to drive or operate complex machinery. A healthcare provider can offer guidance on assessing the medicine's effects before the individual engages in these activities.

Q: Does Menton have a 'Black Box Warning' from the regulatory agencies?

While the term 'Black Box Warning' is specific to the U.S. FDA, official regulatory bodies worldwide issue Serious Warnings and Precautions. Official documents for Menton contain prominent warnings regarding an increased risk of serious ventricular arrhythmias (abnormal heart rhythms) and sudden cardiac death. This risk is heavily emphasized in the safety information.

Q: Does Menton require any regular laboratory tests or monitoring?

The official product information specifies that monitoring should be considered for certain high-risk patients. Individuals who have existing risk factors for heart rhythm problems (QT interval prolongation) should be considered for cardiac monitoring, including an ECG, before and during treatment.

Q: What is the typical expectation for the duration of Menton's effects after a single dose?

Pharmacokinetic studies indicate that the half-life of the medicine in the bloodstream is typically 7 to 9 hours in healthy individuals. The half-life is the time it takes for the concentration of the medicine to be reduced by half. This duration may be longer in patients with severe kidney impairment.

Q: Does Menton have a potential for dependence or misuse?

According to official regulatory information, no habit-forming tendencies have been reported for Menton. The medicine is not classified as a controlled substance.

Q: Is it normal to feel a little dizzy or tired when first starting Menton?

Official product information lists drowsiness (somnolence) and headache as reported adverse reactions. Dizziness has also been reported by some patients. Individuals experiencing these or other symptoms are encouraged to discuss them with their healthcare provider, particularly if the effects are persistent.

Q: Is there a known discontinuation or withdrawal syndrome when stopping Menton?

The official label does not specifically detail a discontinuation or withdrawal syndrome. It is important that any decision to stop the prescribed medicine is reviewed by a doctor, who can provide guidance on the safest way to discontinue use, if necessary.

Q: What should a patient do if they accidentally take more than the prescribed amount of Menton?

Official regulatory information warns that taking more than the prescribed amount can increase the possibility of abnormal heart rhythms and cause symptoms such as confusion or uncontrolled body movements. Management of an overdose usually requires immediate medical attention in a hospital setting due to the risk of serious cardiac events.

Q: Is there a specific patient information leaflet (PIL) for Menton?

Yes, governmental regulatory agencies mandate that pharmaceutical products include official patient-facing documents. These include the Summary of Product Characteristics (SmPC) for professionals and a corresponding Package Leaflet (PIL) for the patient.

How should Menton be stored and disposed of?

How to Store and Dispose of Menton

The following requirements outline the official storage and handling instructions, based on government regulatory documentation for Memantine (the substance referenced in this profile).

Mandatory Storage and Handling

Condition	Requirement
Temperature	Store at room temperature.
Protection	Keep away from excess heat and moisture.
Container	Medication must be kept in its original container and be tightly closed.
Prohibited Areas	Do not store the medication in the bathroom.

Child-Protection Storage

Official instructions mandate that the medication must be secured out of reach of children. Users must always lock safety caps and place the container in a safe, up and away location that is out of a child’s sight and grasp.